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Background. Microalbuminuria has recently been identified
as an independent risk factor for cardiovascular disease in the
general population. Immunochemical urinary albumin assays
only detect immunoreactive intact albumin. High performance
liquid chromatography (HPLC) is able to detect both im-
munoreactive and immunounreactive intact albumin. We com-
pared both measurement methods respectively in subjects
with normo-, micro-, and macroalbuminuria in the general
population.
Methods. We used 24-hour urine samples that were collected
within the framework of the second screening for the PRE-
VEND Study, a prospective cohort study on albuminuria in the
city of Groningen, The Netherlands.
Results. With nephelometry as immunochemical reference
method, we classified 986 subjects as normoalbuminuric, 283 as
microalbuminuric, and 43 subjects as macroalbuminuric. The
mean ± SD albumin concentration was 6.8 ± 4.3 mg/L for
nephelometry in the urine samples of the 998 subjects with
a concentration <20 mg/L according to nephelometry versus
17.6 ± 10.3 mg/L for HPLC (P < 0.001, HPLC 159% higher).
These values were 58.9 ± 40.6 mg/L for nephelometry versus
74.0 ± 51.8 mg/L for HPLC (P < 0.001, N = 280, HPLC 26%
higher) in the concentration range between 20 to 200 mg/L, and
436.3 ± 371.8 mg/L for nephelometry versus 399.1 ± 329.2 mg/L
for HPLC above 200 mg/L (P = 0.048, N = 34, HPLC 8.5%
lower). Associations of 24-hour urinary albumin excretion with
cardiovascular risk factors were generally somewhat stronger
for nephelometry than for HPLC. Logistic regression analyses
with an abnormal ankle-brachial index as outcome parameter
revealed adjusted odds ratios of 1.78 (95%CI 1.01–3.12, P <
0.05) and 4.67 (95%CI 1.68–12.9, P < 0.05) respectively for
micro- and macroalbuminuria as determined by HPLC, com-
pared to 1.37 (95%CI 0.77–2.41, P = NS) and 3.85 (95%CI
1.53–9.67, P < 0.05) respectively for nephelometry. The ROC-
curve showed similar sensitivity and specificity for both methods
(P = 0.25).
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Conclusion. The use of HPLC for determination of urinary al-
bumin concentrations reveals higher values compared to neph-
elometry, especially in the lower concentration range, resulting
in a higher prevalence of microalbuminuria. With HPLC com-
pared to nephelometry, we found a 21% higher independent
odds ratio for microalbuminuria with the presence of periph-
eral vascular disease, and a 30% higher independent odds ratio
for macroalbuminuria.
This higher prevalence of microalbuminuria, accompanied
with a similar absolute risk for peripheral vascular disease com-
pared to patients with microalbuminuria detected by nephelom-
etry, suggests HPLC to identify more people at risk, which is of
great importance, especially when screening in large popula-
tions is concerned.
Microalbuminuria is widely established as one of the
earliest indicators of incipient nephropathy in patients
with type 1 and type 2 diabetes mellitus [1–6]. Early
treatment, guided by annual microalbuminuria testing,
has been shown to slow or even prevent progression to
persistent albuminuria and end-state renal disease [7, 8].
Less well established, but certainly not of lesser impor-
tance, is the fact that albuminuria can be used to identify
subjects at an increased risk of cardiovascular disease.
This was first recognized in patients with type 2 diabetes
mellitus [6, 9, 10], and later extended to patients with type
1 diabetes mellitus [11–14]. Importantly, however, recent
studies indicate that the risk for cardiovascular disease
held by microalbuminuria is also present in the general
population [15–19]. From these studies it became not only
apparent that microalbuminuria is very common in the
general population, with a prevalence of 6.6% even in
subjects without diabetes or hypertension [18], but also
that it is an independent cardiovascular risk factor, even
in subjects with a high normal urinary albumin excretion
[19]. Given the high global incidence of cardiovascular
disease and the availability of adequate preventive treat-
ment modalities, it is of great importance to identify those
people at increased risk of cardiovascular disease as soon,
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and as adequately, as possible. A reliable urinary albumin
assay is obviously of great importance.
Urinary albumin concentrations are traditionally
measured using immunochemical methods, such
as radioimmunoassay, immunoturbidimetry, and
immunonephelometry. The limitation of these assays
is that they can only detect albumin when immunore-
active. Recently, it has been discovered that diabetic
rats excrete appreciable amounts of immunounreactive
intact albumin besides immunoreactive intact albumin
[20]. The presence of immunounreactive intact albumin
has also been demonstrated in urine from diabetic
patients using high-performance liquid chromatography
(HPLC) [21], a method that is capable of measuring both
immunoreactive intact albumin and immunounreactive
intact albumin [22].
We aimed to compare, in the general population, uri-
nary albumin excretion as assessed by a conventional
immunochemical method (immunonephelometry) with
HPLC. To do so, we not only compared the prevalence
of micro- and macroalbuminuria indicated by the differ-
ent methods, but we also investigated the associations
of urinary albumin excretion as determined by the two
methods with other cardiovascular risk factors and with
the presence of peripheral vascular disease.
METHODS
Study population and design
This study is part of the ongoing PREVEND Study
(Prevention of REnal and Vascular ENd stage Disease),
running in the city of Groningen, The Netherlands. De-
tails of the study design and the first screening have
been described elsewhere [23]. Four years after the first
screening, the study participants were invited for a sec-
ond screening consisting of two visits. A total number of
6981 out of the original 8592 subjects visited our outpa-
tient clinic between June 2001 and December 2003. Prior
to the visits subjects were asked to fill out a question-
naire regarding, among others, drug use. Height, weight,
and waist circumferences were measured. During both
visits, systolic and diastolic blood pressure were mea-
sured (Dynamap XL Model 9300 series device) at the
right brachial artery (10 times in total). Within the first
5 minutes, systolic blood pressure at each leg was mea-
sured. Subjects were again asked to collect two 24-hour
urine samples. They received oral and written instructions
on how to collect 24-hour urine samples, and they were
asked to postpone urine collections in case of urinary
tract infection or menstruation, and to refrain of alcohol,
smoking, and heavy exercise during collection as much
as possible. Fasting blood samples were drawn for de-
termination of, among others, glucose, serum creatinine,
total cholesterol, and HDL-cholesterol. Blood pressure
was again measured during this visit. We consecutively se-
lected 1484 subjects (2968 urine samples) from the PRE-
VEND population which we enriched with micro- and
macroalbuminuria. We assessed urinary albumin concen-
trations by nephelometry and by HPLC.
Data handling and definitions
We excluded 172 subjects with either leukocyturia
and/or erytrocyturia. For analytical comparison of both
methods we composed groups with a urinary albumin
concentration of less than 20 mg/L, 20 to 200 mg/L, and
more than 200 mg/L [24]. Analyses of associations with
risk factors and markers of atherosclerosis were per-
formed using categories based on urinary albumin excre-
tion rates (below 30 mg/24hr, 30–300 mg/24hr, and above
300 mg/24hr) [25]. Both analyses were performed using
nephelometry as reference method.
Body mass index (BMI) was calculated by the ratio of
weight and the square of height. Obesity was defined as a
BMI of >30 kg/m2. Systolic and diastolic blood pressure
were calculated as the average of the last two measure-
ments of both visits. Hypertension was defined as systolic
blood pressure ≥140 mm Hg or diastolic blood pressure
of ≥90 mm Hg, or the use of antihypertensive medication.
The ankle-brachial index (ABI) was calculated as the ra-
tio of the systolic blood pressure of the ankle of each leg
and right arm. The lowest ankle-brachial index was used
in the analysis. Peripheral artery disease was defined as
an ankle-brachial index <0.9 [26].
Laboratory methods
Urinary immunoreactive albumin was measured by
immunonephelometry (Behring Nephelometer, using
reagents from Dade Behring Diagnostics, Marburg,
Germany), with a threshold of 1.8 to 2.3 mg/L, and
intra- and interassay coefficients of variation of less than
2.2% and 2.6%, respectively. Total urinary intact albu-
min (immunoreactive plus immunounreactive) was mea-
sured using an Agilent/Hewlett Packard 1100 HP series
based on size-exclusion HPLC. Aliquots of urine [25 lL
were injected onto a Zorbax Bio series preparative GF
250 column (9.4-mm ID × 25 mm)]. The mobile phase
was phosphate-buffered saline (PBS) run at a flow of 1
mL/min. Blood glucose was determined by ECA 180 (De-
pex; Houten, The Netherlands). Serum and urinary crea-
tinine, and serum total cholesterol and HDL-cholesterol
were determined by MEGA (Merck, Darmstadt,
Germany). Urinary leukocyte and erythrocyte mea-
surements were done by Nephur-test + leuco sticks
(Boehringer Mannheim, Mannheim, Germany).
Statistical analysis
Analyses were performed using SPSS 10.0 (SPSS,
Chicago, IL, USA). The significance level was determined
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Table 1. Population characteristics according to categories of albuminuria as detected by nephelometry
<30 mg/24hr (N = 986) 30 to 300 mg/24hr (N = 283) >300 mg/24hr (N = 43) P valueb
Male gender % 52.3 67.8 81.4 <0.001
Age years 52 (12) 60 (11) 62 (10) <0.001
Body mass index kg/m2 26.4 (4.1) 28.3 (4.7) 30.8 (4.9) <0.001
Obesity % 17.2 30.7 41.9 <0.001
Smoking % 28.9 25.7 9.3 <0.001
Waist cm 96.3 (11.3) 101.4 (11.0) 108.2 (9.9) <0.001
Men
Women 86.7 (11.9) 93.9 (15.8) 95.8 (15.6) <0.001
Diabetes mellitus % 1.9 12.0 18.6 <0.001
Glucose mmol/L 4.8 (0.9) 5.5 (1.6) 6.1 (2.0) <0.001
Antidiabetic drugs % 1.8 13.9 20.9 <0.001
Systolic blood pressure mm Hg 125 (18) 139 (20) 150 (24) <0.001
Diastolic blood pressure mm Hg 73 (9) 78 (9) 82 (10) <0.001
Hypertension % 28.0 59.9 79.1 <0.001
Antihypertensive drugs % 15.7 35.8 51.2 <0.001
Cholesterol mmol/L 5.4 (1.1) 5.5 (1.1) 5.4 (1.1) NS
HDL cholesterol mmol/L 1.04 (0.29) 0.96 (0.29) 0.95 (0.30) <0.001
Lipid lowering drugs % 7.8 20.0 23.3 <0.001
Creatinine clearance mL/min 101.2 (24.8) 100.6 (31.0) 94.6 (32.4) NS
UAE nephelometrya mg/24hr 8.3 (6.1–12.9) 62.5 (40.2–107.9) 517.0 (364.5–780.6) <0.001
UAE HPLCa mg/24hr 24.5 (17.8–34.1) 84.9 (56.9–134.1) 531.5 (321.6–780.6) <0.001
ABI % impaired 6.7 14.0 28.6 <0.001
aData with a skewed distribution are presented as median (interquartile range).
bP value using ANOVA for continuous data (log-transformed in case of a skewed distribution) and chi-square for percentages.
at P < 0.05. Continuous data were reported as mean with
standard deviation. Skewed distributions were expressed
as median with interquartile range. Analytical compari-
son of both methods was performed using linear regres-
sion and Bland-Altman plots. For comparison between
prevalences, chi-square analysis was carried out. Contin-
uous data with a skewed distribution were transformed
toward a normal distribution by log-transformation. For
urinary albumin excretion we applied log-log transforma-
tion to normalize the distribution. Mean values of contin-
uous data were compared between groups by analysis of
variance (ANOVA) or paired t test (for comparison be-
tween urinary albumin concentrations by nephelometry
and HPLC). To study the association of urinary albumin
excretion as assessed by nephelometry and HPLC with
cardiovascular risk factors and markers of atheroscle-
rosis, we used Pearson’s correlation analyses. We used
logistic regression to study the association between al-
buminuria classes with diminished ABI. After analyzing
crude odds ratios, adjustments were made for age and
gender. In a subsequent model we additionally adjusted
for BMI, glucose, systolic and diastolic blood pressure,
use of antihypertensive drugs, serum total cholesterol,
HDL-cholesterol, lipid-lowering therapy, and smoking.
ROC curves were compared according to the method de-
scribed by Hanley and McNeil.
RESULTS
Population characteristics
The characteristics of the subjects described for the
various UAE groups as measured by nephelometry are
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Fig. 1. Bland-Altman plot for nephelometry and HPLC. The dashed
lines represent the zero bias line ± 1.96 SD limits.
shown in Table 1. The results are consistent with an
increased prevalence of cardiovascular risk factors in
subjects with either micro- or macroalbuminuria. Only
smoking was less prevalent in the macroalbuminuric
subjects. Urinary albumin excretions were remarkably
higher in the normo- and microalbuminuria subjects
when measured by HPLC compared to nephelometry.
Of special note is the high prevalence of an abnormal
ABI in subjects with micro- and macroalbuminuria com-
pared to normoalbuminuric subjects (14.0% and 28.6%,
respectively, vs. 6.7%).
Comparison between nephelometry and HPLC
Figure 1 shows a Bland-Altman bias plot for both as-
says. Data were log-transformed before plotting because
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Fig. 2. Scatter plots and regression lines calculated using the least
square method to determine the relation between nephelometry and
HPLC, according to categories of urinary albumin concentrations
(UAC). (A) Albumin concentration below 20 mg/L. (B) Albumin con-
centration between 20 and 200 mg/L. (C) Albumin concentration above
200 mg/L.
of the large concentration range studied. There is an in-
creasing amount of bias with decreasing urinary albumin
concentrations. The scatter plot in Figure 2A provides
a closer view on the normoalbuminuric concentration
range, according to nephelometry. The mean ± SD of the
urinary albumin concentrations as determined by neph-
elometry in the urine samples of the 998 subjects in this
Table 2. Agreement between categories of albuminuria as
determined by nephelometry versus HPLC
HPLC albuminuria classes
<30 30 to 300 >300
mg/24hr mg/24hr mg/24hr
(N = 662) (N = 609) (N = 41) %
Nephelometry albuminuria classes
<30 mg/24hr (N = 986) 649 337 75.2
30–300 mg/24hr (N = 283) 13 264 6 21.6
>300 mg/24hr (N = 43) 8 35 3.2
% 50.5 46.4 3.1
Table 3. Pearson correlations with albuminuria as determined by
nephelometry and HPLC
Nephelometer HPLC
Gender −0.22a −0.22a
Age 0.30a 0.28a
Body mass index 0.28a 0.17a
Obesity 0.21a 0.12a
Smoking −0.05 0.00
Waist 0.36a 0.26a
Diabetes mellitus 0.22a 0.23a
Glucose 0.28a 0.29a
Antidiabetic drugs 0.24a 0.25a
Systolic blood pressure 0.40a 0.33a
Diastolic blood pressure 0.36a 0.30a
Hypertension 0.36a 0.28a
Antihypertensive drugs 0.25a 0.20a
Cholesterol 0.04 0.03
HDL-cholesterol −0.17a −0.12a
Lipid lowering drugs 0.17a 0.15a
Creatinine clearance 0.07a 0.02
ABI 0.13a 0.16a
aSignificant at the 0.01 level.
range was 6.78 ± 4.27 mg/L versus 17.6 ± 10.3 mg/L for
HPLC (P < 0.001), a 159% difference. Figures 2B and C,
respectively, show the scatter plots for the microalbumin-
uric and the macroalbuminuric concentration range. The
mean ± SD of nephelometry was 58.9 ± 40.6 mg/L ver-
sus 74.0 ± 51.8 mg/L for HPLC (HPLC 26% higher, P <
0.001) in the 280 subjects with nephelometric concentra-
tions between 20 to 200 mg/L, and 436 ± 371 mg/L for
nephelometry versus 399 ± 329 mg/L for HPLC (HPLC
8.5% lower, P = 0.048) in the 34 subjects in the range
above 200 mg/L.
Following these analyses, we also investigated the
agreement between both methods, based on 24-hour uri-
nary albumin excretion rates. The results of this com-
parison are shown in Table 2. Thirteen (2.0%) out of
662 subjects that were classified as normoalbuminuric
by HPLC were classified as microalbuminuric by neph-
elometry, while 337 (34.2%) out of 986 subjects that
were classifed as normoalbuminuric by nephelometry
were classified as microalbuminuric by HPLC. In the
macroalbuminuric range, 35 subjects were classifed as
macroalbuminuric by both methods, on 43 subjects with
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Fig. 3. Odds ratios of a diminished ankle-brachial index according to
categories of urinary albumin excretion determined by nephelometry
and HPLC. ∗P < 0.05, ∗∗P < 0.001.
macroalbuminuria as classified by nephelometry, and 41
subjects with macroalbuminuria as classified by HPLC.
Table 3 shows Pearson correlation coefficients for the
associations of 24-hour urinary albumin excretion rates
as determined by nephelometry and HPLC with cardio-
vascular risk factors and several other variables. This
analysis showed a slightly stronger association of urinary
albumin excretion as determined by nephelometry with
age, body mass index, obesity, waist circumference, sys-
tolic blood pressure, diastolic blood pressure, hyperten-
sion, use of antihypertensive drugs, HDL-cholesterol, use
of lipid-lowering drugs, and creatinine clearance, while
urinary albumin excretion as determined by HPLC was
somewhat more strongly associated with the presence
of diabetes mellitus, fasting glucose concentrations, and
use of antidiabetic drugs. Despite the fact that the asso-
ciations with cardiovascular risk factors were generally
somewhat stronger for urinary albumin excretion rates
as determined by nephelometry, we found the strongest
association of urinary albumin excretion as determined
by HPLC with the outcome parameter in our study, an
abnormal ABI.
Logistic regression analyses with an abnormal
ankle-brachial index as outcome parameter
Figure 3 shows the logistic regression analyses that we
performed to determine whether HPLC predicts ABI in
a similar way as nephelometry, either unadjusted or after
adjustment for cardiovascular risk markers. The unad-
justed odds ratio for macroalbuminuria as determined
with HPLC (with normoalbuminuria as determined with
HPLC as reference group) was 9.10 (95%CI 3.98–20.8,
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Fig. 4. ROC analysis of HPLC and nephelometry according to a dimin-
ished ankle-brachial index. HPLC is represented by the gray line, and
nephelometry by the black line. The dashed line is the line of identity.
P < 0.001). Nephelometry showed an odds ratio of 7.20
(95%CI 3.41–15.2, P < 0.001) for macroalbuminuria
(with normoalbuminuria as determined with nephelom-
etry as reference group). All odds ratios decreased af-
ter adjustment for other risk factors. However, the odds
ratio for macroalbuminuria as determined by HPLC,
4.67 (95%CI 1.68–12.9, P < 0.05), remained higher than
the odds ratio for macroalbuminuria as determined by
nephelometry, 3.85 (95%CI 1.53–9.67, P < 0.05), a 30%
difference. For microalbuminuria the unadjusted odds
ratio for HPLC was 2.54 (95%CI 1.53–4.21, P < 0.001),
and 2.39 (95%CI 1.46–3.91, P < 0.001) for nephelometry.
These values are 1.78 (95%CI 1.01–3.12, P < 0.05) and
1.37 (95%CI 0.77–2.41, P = NS), respectively, for HPLC
and nephelometry after adjustment for all other risk fac-
tors, a 21% difference.
A comparison of the predictive performance of both
methods using ROC curve analysis (Fig. 4) showed that
there was no significant difference in the area under the
curve (AUC) between HPLC and nephelometry [AUC
0.67 (95%CI 0.61–0.73) vs. 0.65 (95%CI 0.58–0.71), re-
spectively, P = 0.25].
DISCUSSION
We compared urinary albumin concentrations and 24-
hour urinary albumin excretion rates as determined by
nephelometry versus HPLC in a selected subsample of
the general population. Nephelometry only measures im-
munoreactive intact albumin, whereas HPLC measures
both immunoreactive and immunounreactive intact al-
bumin [27]. As might be anticipated from this differ-
ence between both techniques, we found higher urinary
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albumin concentrations in subjects using HPLC com-
pared to nephelometry in the normoalbuminuric range
(<20 mg/L). This is quite consistent with the fact that
HPLC measures the same amount of immunoreactive in-
tact albumin as nephelometry, plus some amount of im-
munounreactive intact albumin. From the relatively low
correlation between the two methods (r = 0.61) in this uri-
nary albumin concentration range, it can be seen that it is
not a constant factor which is just added upon the amount
of immunoreactive intact albumin. Interestingly, in the
higher urinary albumin concentration ranges, we did not
find any indication of any additional albumin, the regres-
sion lines almost equals the line of identity (y = x) and
the mean value in the macroalbuminuric range was even
8.5% lower with HPLC than with nephelometry. Cor-
relation coefficients in the higher concentration ranges
were slightly higher for the micro- and much higher for
macroalbuminuric range, respectively. Our explanation
for the fact that HPLC only provides higher values in
samples with low urinary albumin concentrations is that
not all immunoreactive intact albumin can be detected by
currently available immunochemical methods due to as
yet not otherwise identifiable insensitivity of the meth-
ods in the lower concentration ranges. Other potential
explanations have been listed by Comper et al [21].
In direct relation to the relatively high urinary albu-
min concentrations detected by HPLC in the low urinary
albumin concentration range, we found poor agreement
between both methods in classifying subjects as normo-
or microalbuminuric on the basis of 24-hour urinary
albumin excretion rates. We confirmed the known as-
sociations of urinary albumin excretion with age, gen-
der, and several cardiovascular risk factors. Correlations
of urinary albumin excretion as detected by HPLC with
these known associates were generally weaker than with
urinary albumin excretion as detected by nephelometry.
When it comes to identifying subjects with prevalent pe-
ripheral vascular disease, indicated by a low ABI, HPLC
might be a better predictor. Which was shown by the
higher odds ratios for micro- and macroalbuminuria as
determined by HPLC.
Several points concerning our study have to be ad-
dressed. Our finding of much higher urinary albumin con-
centrations using HPLC than nephelometry, but only in
normoalbuminuric range (<20 mg/L) is consistent with
findings of a comparison between the use of HPLC and
radioimmunoassay for urinary albumin detection in urine
samples from 97 diabetic patients [21]. In this latter study,
HPLC also revealed relatively high values in the low uri-
nary albumin concentration range and essentially equiv-
alent results in the higher range. It was suggested that this
is specific for subjects with diabetes, because in 78 nondi-
abetic control subjects with low urinary albumin concen-
trations, values revealed by HPLC were nonsignificantly
(P = 0.07) higher (7.5 ± 6.6 mg/L vs. 5.3 ± 4.5 mg/L) than
the values revealed by RIA. However, our results indicate
a highly significant difference in the general population.
It seems likely that the previous study was underpowered
to draw conclusions about the absence of a difference in
the nondiabetic population [21].
Future studies are necessary to elaborate the potential
superiority of urinary albumin determination by HPLC
over nephelometry for determination and prediction of
(cardio)vascular disease. It should be realized that our
study has several limitations. First, our study is cross-
sectional in nature and can, therefore, only be con-
sidered as hypothesis generating. Firm conclusions can
only be drawn from a prospective cohort study. Second,
it should be realized that we investigated a selected
study population with a relatively high prevalence of
micro- and macroalbuminuria. The prevalences of micro-
and macroalbuminuria according to nephelometry in
our study population were 21.6% and 3.2%, respec-
tively. These are much higher prevalences than the
12.1% and 1.1%, respectively, in the original, already
for microalbuminuria-enriched cohort [23]. The actual
prevalence of microalbuminuria in the general Dutch
population is estimated to 7% [18]. Thus, our study pop-
ulation is not representative for the general population.
Another complication which decreases the generalizabil-
ity of our results to the general population is the fact that
we used data collected in subjects that have been made
aware of the results of the first screening of the PRE-
VEND population. It is not unlikely that this has diverted
the study population away from the characteristic of the
general population. One example is the smoking preva-
lence in our study sample. During the first screening we
found a smoking prevalence of 44.3% for normoalbumin-
uric subjects, 46.7% for microalbuminuric subjects, and
45.1% for macroalbuminuric subjects (P = NS) [23]. The
smoking prevalence by classification according to neph-
elometry in our study sample is much lower, especially in
the subjects with macroalbuminuria. One possible expla-
nation is that awareness of their increased cardiovascular
risk motivated relatively many subjects with macroalbu-
minuria to stop smoking between the two screenings.
It should be realized that we used the same classic
cut-off values for micro- and macroalbuminuria for both
nephelometry and HPLC. This resulted in relatively few
cases of normoalbuminuria and relatively more cases
of microalbuminuria with HPLC compared to neph-
elometry, because HPLC provides higher values espe-
cially in the low range of concentrations. The number
of macroalbuminuric subjects was roughly the same with
both methods. Thus, using the 30 mg/24hr cut-off point,
more patients were identified as having microalbumin-
uria with HPLC than with nephelometry. Notwithstand-
ing, those patients identified by HPLC had a similar
absolute risk for prevalent peripheral vascular disease
(diminished ABI) when compared to those identified
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with nephelometry (29 out of 283 patients vs. 53 out of 609
patients, respectively; NS). When confirmed in prospec-
tive studies, these findings may have consequences for
population screening since measuring albuminuria with
HPLC will identify more people at risk.
CONCLUSION
We have shown that detection of total intact urinary
albumin by HPLC provides different values than neph-
elometry, which only measures immunoreactive intact
albumin. The difference between the two methods is
especially present in the normoalbuminuric concentra-
tion range. Urinary albumin excretion as determined by
nephelometry is generally somewhat stronger correlated
to cardiovascular risk factors, but HPLC was more
strongly related to prevalent peripheral vascular disease,
with a 21% higher independent odds ratio for microal-
buminuria, and a 30% higher independent odds ratio for
macroalbuminuria. The higher prevalence of microalbu-
minuria we saw when using HPLC, accompanied with
a similar absolute risk for peripheral vascular disease
compared to patients with microalbuminuria detected by
nephelometry, suggests HPLC to identify more people at
risk, which is of great importance, especially when screen-
ing in large populations is concerned. However, future
research is needed because our study was cross-sectional
in a selected population.
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